These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism. Hassa H; Tanir HM; Yildiz Z Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383 [TBL] [Abstract][Full Text] [Related]
5. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824 [TBL] [Abstract][Full Text] [Related]
10. Polycystic Ovary Syndrome in Adolescents. Witchel SF; Roumimper H; Oberfield S Endocrinol Metab Clin North Am; 2016 Jun; 45(2):329-44. PubMed ID: 27241968 [TBL] [Abstract][Full Text] [Related]
11. New perspectives on the definition and management of polycystic ovary syndrome. Pasquali R; Gambineri A J Endocrinol Invest; 2018 Oct; 41(10):1123-1135. PubMed ID: 29363047 [TBL] [Abstract][Full Text] [Related]
12. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Kazerooni T; Dehghan-Kooshkghazi M Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019 [TBL] [Abstract][Full Text] [Related]
13. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450 [TBL] [Abstract][Full Text] [Related]
14. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Diamanti-Kandarakis E; Kouli CR; Bergiele AT; Filandra FA; Tsianateli TC; Spina GG; Zapanti ED; Bartzis MI J Clin Endocrinol Metab; 1999 Nov; 84(11):4006-11. PubMed ID: 10566641 [TBL] [Abstract][Full Text] [Related]
15. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. Spritzer PM Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):182-7. PubMed ID: 24830595 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China. Feng JG; Guo Y; Ma LA; Xing J; Sun RF; Zhu W J Cosmet Dermatol; 2018 Jun; 17(3):511-517. PubMed ID: 28940857 [TBL] [Abstract][Full Text] [Related]
17. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Harwood K; Vuguin P; DiMartino-Nardi J Horm Res; 2007; 68(5):209-17. PubMed ID: 17426408 [TBL] [Abstract][Full Text] [Related]
18. Obesity and the polycystic ovary syndrome. Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153 [TBL] [Abstract][Full Text] [Related]
19. Endocrine characteristics of polycystic ovary syndrome (PCOS). Szilágyi A; Szabó I Indian J Exp Biol; 2003 Jul; 41(7):694-700. PubMed ID: 15255372 [TBL] [Abstract][Full Text] [Related]
20. Androgen excess disorders in women: the severe insulin-resistant hyperandrogenic syndrome, HAIR-AN. Rager KM; Omar HA ScientificWorldJournal; 2006 Jan; 6():116-21. PubMed ID: 16435040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]